:: Library Catalog

Image de couverture de livre

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	C. Gaume, C. Moluçon Chabrot, P. Chabrot, A. Abergel
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	https://onlinelibrary.wiley.com/doi/10.1111/apt.17840
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
par: Maria Gabriela Fernandes Dezan, et autres
Publié: (2024)

Editorial: Have you asked your patients about their difficulties in paying the medical costs of their treatment?
par: Abergel Armand, et autres
Publié: (2024)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
par: J. Ventre, et autres
Publié: (2025)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
par: David Uihwan Lee, et autres
Publié: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
par: C. Stephens
Publié: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
par: Lisa Sandmann, et autres
Publié: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index in predicting mortality and guiding prehabilitation
par: Sara J. Harris, et autres
Publié: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply
par: Matthew J. Armstrong, et autres
Publié: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
par: Wenjun Meng, et autres
Publié: (2024)

Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply
par: Walter W. Chan, et autres
Publié: (2026)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
par: Sung Won Chung, et autres
Publié: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
par: Jian Wang, et autres
Publié: (2024)

Editorial: The future of managing drug induced liver injury
par: Amanda Nicoll
Publié: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question
par: Jenny Lövdahl, et autres
Publié: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
par: Carolin V. Schneider, et autres
Publié: (2024)

Characterisation of an outbreak of acute liver injury after ingestion of plant‐based food supplement
par: Gina Choi, et autres
Publié: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
par: Dipesh H. Vasant, et autres
Publié: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
par: Ivan Arcari, et autres
Publié: (2024)

Review article: advances in the diagnosis and management of anorectal motility disorders
par: Dariush Shahsavari, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
par: Richie Manikat, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
par: Abdel‐Aziz Shaheen, et autres
Publié: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
par: Shusuke Kumazaki, et autres
Publié: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
par: Giammarco Mocci, et autres
Publié: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
par: Maria Ling Lundström, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
par: Basile Njei, et autres
Publié: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
par: Stuart McPherson, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
par: Manya Prasad, et autres
Publié: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
par: Mohamed I. Elsaid, et autres
Publié: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
par: Xianhua Mao, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
par: Eunice X. X. Tan, et autres
Publié: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
par: Victoria T. Kronsten, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
par: Samer Gawrieh, et autres
Publié: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
par: Richie Manikat, et autres
Publié: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
par: Philip Vutien, et autres
Publié: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
par: Mark C. C. Cheah, et autres
Publié: (2025)

Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients
par: Anna Fettiplace, et autres
Publié: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
par: Min Wu, et autres
Publié: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
par: Jannis Kountouras, et autres
Publié: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
par: Ming‐Lun Yeh, et autres
Publié: (2024)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
par: Nina Kimer, et autres
Publié: (2024)